07:00 , Jul 23, 2012 |  BioCentury  |  Finance

Crash diet

Despite a 10% pop following last Tuesday's FDA approval of obesity drug Qsymia , Vivus Inc. ended the week off $3.02 (11%) at $24.15 - the stock's lowest close since mid-May. The downward pressure came...
07:00 , Apr 2, 2001 |  BioCentury  |  Finance

Ebb & Flow

For years the industry has struggled to put a valuation on early stage research. Banc of America analyst Jim Reddoch provided a series of benchmarks he uses to value genomics and post-genomics companies, as well...
07:00 , Oct 11, 2000 |  BC Extra  |  Company News

Aviron FluMist deals

AVIR on Wednesday made two moves that will give the company primary responsibility for the manufacturing of its FluMist intranasal flu vaccine. AVIR restructured a FluMist manufacturing deal with Evans Vaccines (Oxford, U.K.), and leased...
08:00 , Nov 16, 1998 |  BioCentury  |  Finance

Testing the IPO waters

Testing the IPO waters MARKET HOPEFULS: Sensus Drug Development (Proposed:SDDC) is planning a 3 million share IPO at $13-$15 per share. A $14 price would value the company at $134.4 million. The underwriters - Merrill...
08:00 , Feb 2, 1998 |  BioCentury  |  Finance

Running for cover

Investors on Friday initially drove up shares of Advanced Tissue Sciences (ATIS) and Organogenesis (ORG) after Thursday's General and Plastic Surgery Devices Panel recommended approval of both companies' skin products (see BioCentury Extra, Jan. 30)...
08:00 , Jan 5, 1998 |  BioCentury  |  Finance

Last Week: Pump up the volume

In the seven days between Dec. 8 and Dec. 16, the shares dropped from $6 to $2.875. The price had rebounded to $3.50 prior to the FDA letter, still well off the $10.875 it hit...